Lub Helsen Akynzeo Intravenous Npaj Tau Pom Zoo Los Ntawm European Union, Thiab Lub Chaw Nkoj Tau Ua Tau Hauv Suav Teb!

Swiss tus kws kho mob pawg Helson pab pawg tsis ntev los no tshaj tawm tias European Commission (EC) tau pom zoo Akynzeo (fosnetupitant 235mg / palonosetron 0 25mg) kev tso ntshav (IV) raws li lwm txoj kev kho mob los tiv thaiv kev kho mob - vim yauv tsum thiab ntuav (CINV).

Hauv Tebchaws Europe, Akynzeo qhov ncauj tawv nyuaj (netupitant 300mg / palonosetron 0. 5mg) tau pom zoo rau xyoo 2015 rau kev tiv thaiv mob hnyav lossis qeeb CINV hauv cov neeg mob uas tau txais kev kho mob siab thiab mob me me emetic tshuaj kho mob.

Helsinn submitted a marketing authorization application (MAA) for Akynzeo IV in November 2018 as an extension of Akynzeo hard capsules. In December 2019, the European Medicines Agency (EMA) Committee for Human Pharmaceutical Products (CHMP) issued a positive review opinion in support of approval. The approval of Akynzeo IV preparation will provide an alternative route of administration for European patients and healthcare providers.

Nws tsim nyog teev tias Akynzeo tsuas yog kho kom zoo - koob tshuaj tiv thaiv kev sib xyaw ua ke uas tuaj yeem sib txuas ua ke ob qhov sib txawv CINV txoj hauv kev los ntawm ib - koob tshuaj kho. Akynzeo tso ntshav npaj (IV) yog qhov tsau tshiab - koob tshuaj sib xyaw ua ke npaj ua los ntawm fosnetupitant thiab palonosetron; ntawm lawv, fosnetupitant yog netupitant prodrug uas ua kom dej solubility thiab ua kom muaj kev txhaj tshuaj, uas tuaj yeem hloov mus rau netupitant hauv lub cev, qhov tom kawg yog xaiv tau NK1 receptor antagonist; palonosetron (palonosetron) yog 5 - HT3 receptor antagonist.

In China, Akynzeo capsules were approved on August 2, 2019 for adult patients: prevention of acute nausea and vomiting caused by highly emetic chemotherapy and delayed nausea and vomiting, prevention of acute nausea and vomiting caused by moderate emetic chemotherapy And delayed nausea and vomiting. Mengdi Chinese Pharmaceutical Company owns the exclusive marketing and sales rights of Akynzeo® Capsules in China,

Txawm hais tias muaj ntau cov tshuaj, CINV tswj hwm hauv ntau tus neeg mob qog nqaij hlav cancer hauv kev kho mob yuav tseem tsis zoo. Akynzeo tsiav tshuaj thiab Akynzeo txhaj tshuaj npaj tau ib txhij thaiv ob txoj kev sib cuam tshuam ntawm CINV hauv ib txoj kev tswj hwm nkaus xwb, uas tuaj yeem pab cov neeg mob thiab lawv tsev neeg txhim kho lawv lub neej zoo.